^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TSC2 mutation

    i
    Other names: TSC2, TSC Complex Subunit 2, Protein Phosphatase 1, Regulatory Subunit 160, Tuberous Sclerosis 2 Protein, Tuberin, TSC4, Tuberous Sclerosis 2, PPP1R160
    Entrez ID:
    7249
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations (NCT03047213)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    08/24/2017
    Primary completion :
    10/06/2020
    Completion :
    11/11/2025
    TSC2 • TSC1
    |
    TSC1 mutation • TSC2 mutation
    |
    sapanisertib (CB-228)
    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    11/28/2017
    Primary completion :
    09/30/2023
    Completion :
    10/01/2024
    PTEN • TSC2 • TSC1
    |
    PTEN expression • TSC1 mutation • TSC2 mutation
    |
    samotolisib (LY3023414)
    Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children (NCT03649919)
    Phase N/A
    Children's Hospital of Fudan University
    Withdrawn
    Last update posted :
    08/11/2021
    Initiation :
    09/30/2021
    Primary completion :
    10/30/2021
    Completion :
    12/30/2021
    TSC2 • TSC1
    |
    TSC1 mutation • TSC2 mutation • TSC1 deletion
    Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations (NCT02352844)
    Phase 2
    Washington University School of Medicine
    Completed
    Last update posted :
    10/02/2018
    Initiation :
    10/07/2015
    Primary completion :
    08/15/2017
    Completion :
    08/15/2017
    STK11 • NF1 • TSC2 • TSC1
    |
    NF1 mutation • TSC1 mutation • TSC2 mutation
    |
    everolimus
    Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations (NCT03108261)
    Phase 2
    Yale University
    Not yet recruiting
    Last update posted :
    11/21/2017
    Initiation :
    05/01/2017
    Primary completion :
    12/31/2018
    Completion :
    12/31/2020
    TSC2 • TSC1
    |
    TSC1 mutation • TSC2 mutation
    |
    sapanisertib (CB-228)